Douglas Tsao Analyst PerformanceSenior Analyst at HC WainwrightDouglas Tsao is a stock analyst at HC Wainwright in the medical sector, covering 36 publicly traded companies. Over the past year, Douglas Tsao has issued 67 stock ratings, including buy and hold recommendations. While full access to Douglas Tsao's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Douglas Tsao's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings211 Last 11 YearsBuy Recommendations86.26% 182 Buy RatingsCompanies Covered36 Unique Companies Ratings Distribution211RatingsDistribution of strong buy, buy, hold, and sell ratings by Douglas Tsao.RatingPercentageCount Strong Buy0.0%0 ratings Buy86.3%182 ratings Hold13.7%29 ratings Sell0.0%0 ratingsOut of 211 total stock ratings issued by Douglas Tsao at HC Wainwright, the majority (86.3%) have been Buy recommendations, followed by 13.7% Hold.Best & Worst CallsBest Call0000.0%PRAXMar 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%BHCJul 2015Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ80.6% of companies on NASDAQ29 companiesNYSE16.7% of companies on NYSE6 companiesNYSEAMERICAN2.8% of companies on NYSEAMERICAN1 companyDouglas Tsao, an analyst at HC Wainwright, currently covers 36 companies listed on NASDAQ, NYSE and NYSEAMERICAN, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical36 companies100.0%Douglas Tsao of HC Wainwright specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE22 companies61.1%MED - DRUGS6 companies16.7%MED PRODUCTS2 companies5.6%PHARMACEUTICAL PREPARATIONS2 companies5.6%MED - GENERIC DRG2 companies5.6%BIOTECHNOLOGY1 company2.8%MED INSTRUMENTS1 company2.8% About Douglas TsaoMr. Tsao is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on Biopharmaceuticals and Specialty Pharmaceuticals. Specific therapeutics areas include Endocrinology, Metabolic disease, Dermatology, and CNS in addition to other areas. Prior to joining H.C. Wainwright, Mr. Tsao was a senior equity research analyst at Barclays covering U.S. Specialty Pharmaceutical companies as well as small and midcap medical device companies. Mr. Tsao is recognized for his expertise in biosimilars and is a frequent speaker on this topic at industry conferences. Prior to Barclays Mr. Tsao worked at Lehman Brothers and his combined experience spans over ten years at these two firms. Mr. Tsao served as a Special Assistant to U.S. EPA Administrator Carol Browner from 1997-1999, received an MBA/MPH from U.C. Berkeley and graduated cum laude from Middlebury College with High Honors.Follow on LinkedIn Douglas Tsao's Ratings History at HC Wainwright Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsPCRXPacira BioSciences7/1/2026Reiterated Rating$25.37$38.00Buy$0.0000.00% ROIARGXargenex6/25/2026Reiterated Rating$852.50$940.00Buy$0.0000.00% ROINMRANeumora Therapeutics6/16/2026Lower Price Target$0.91$7.00Buy$0.0000.00% ROICRNXCrinetics Pharmaceuticals6/15/2026Reiterated Rating$34.47$81.00Buy$0.0000.00% ROIPRAXPraxis Precision Medicines6/2/2026Lower Price Target$335.16$1,201.00Buy$0.0000.00% ROIRZLTRezolute6/2/2026Reiterated Rating$3.94$5.00Buy$0.0000.00% ROIPRAXPraxis Precision Medicines5/26/2026Reiterated Rating$343.56$1,245.00Buy$0.0000.00% ROIBHVNBiohaven5/26/2026Reiterated Rating$10.19$10.00Neutral$0.0000.00% ROIROIVRoivant Sciences5/21/2026Reiterated Rating$32.41$34.00Buy$0.0000.00% ROIIMVTImmunovant5/21/2026Boost Price Target$35.56$40.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. PRAXPraxis Precision Medicines4/7/2026Reiterated Rating$310.11$1,245.00Buy$0.0000.00% ROIAPLSApellis Pharmaceuticals4/1/2026Downgrade$40.23$41.00Hold$0.0000.00% ROIVRDNViridian Therapeutics3/31/2026Lower Price Target$18.53$22.00Buy$0.0000.00% ROINERVMinerva Neurosciences3/12/2026Reiterated Rating$7.30$7.00Neutral$0.0000.00% ROIXENEXenon Pharmaceuticals3/10/2026Boost Price Target$62.76$74.00Buy$0.0000.00% ROIBHVNBiohaven3/4/2026Lower Price Target$10.66$10.00Neutral$0.0000.00% ROIROIVRoivant Sciences3/4/2026Boost Price Target$27.85$34.00Buy$0.0000.00% ROITBPHTheravance Biopharma3/2/2026Boost Price Target$18.25$27.00Buy$0.0000.00% ROIARGXargenex2/27/2026Boost Price Target$771.53$940.00Buy$0.0000.00% ROIARQTArcutis Biotherapeutics2/26/2026Boost Price Target$27.01$34.00Buy$0.0000.00% ROIALKSAlkermes2/26/2026Reiterated Rating$31.04$43.00Neutral$0.0000.00% ROIAPLSApellis Pharmaceuticals2/25/2026Boost Price Target$22.13$48.00Buy$0.0000.00% ROIOTLKOncobiologics2/18/2026Reiterated Rating$0.42Neutral$0.0000.00% ROIROIVRoivant Sciences2/10/2026Boost Price Target$27.67$33.00Buy$0.0000.00% ROIIMVTImmunovant2/10/2026Reiterated Rating$27.49$35.00Buy$0.0000.00% ROIEOLSEvolus2/3/2026Lower Price Target$4.91$13.00Buy$0.0000.00% ROIPTGXProtagonist Therapeutics1/30/2026Boost Price Target$79.73$117.00Buy$0.0000.00% ROIPRAXPraxis Precision Medicines1/30/2026Reiterated Rating$314.28$1,245.00Buy$0.0000.00% ROIPCRXPacira BioSciences1/9/2026Reiterated Rating$26.02$38.00Buy$0.0000.00% ROIEOLSEvolus1/9/2026Reiterated Rating$5.50$20.00Buy$0.0000.00% ROIPRAXPraxis Precision Medicines12/30/2025Reiterated Rating$304.58Buy$0.0000.00% ROIBHVNBiohaven12/26/2025Reiterated Rating$9.06$11.00Neutral$0.0000.00% ROIROIVRoivant Sciences12/12/2025Boost Price Target$21.56$26.00Buy$0.0000.00% ROIRZLTRezolute12/12/2025Lower Price Target$1.40$5.00Buy$0.0000.00% ROIRAPPRapport Therapeutics12/9/2025Boost Price Target$30.16$40.00Buy$0.0000.00% ROIPRAXPraxis Precision Medicines12/5/2025Reiterated Rating$189.97$340.00Buy$0.0000.00% ROIBHVNBiohaven12/3/2025Downgrade$8.85$11.00Neutral$0.0000.00% ROIDAREDare Bioscience12/2/2025Reiterated Rating$1.67$12.00Buy$0.0000.00% ROIPRAXPraxis Precision Medicines11/25/2025Reiterated Rating$190.85$258.00Buy$0.0000.00% ROIPCRXPacira BioSciences11/17/2025Reiterated Rating$23.78$38.00Buy$0.0000.00% ROITicker Revealed: Pre-IPO Access to "Next Elon Musk" Company (Ad)We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.👉 Unlock the ticker now and get it completely free.PRAXPraxis Precision Medicines11/13/2025Boost Price Target$183.61$258.00Buy$0.0000.00% ROITBPHTheravance Biopharma11/11/2025Boost Price Target$15.08$20.00Buy$0.0000.00% ROINERVMinerva Neurosciences11/6/2025Lower Price Target$3.82$4.00Neutral$0.0000.00% ROIAPLSApellis Pharmaceuticals10/31/2025Lower Price Target$20.73$45.00Buy$0.0000.00% ROIARGXargenex10/31/2025Boost Price Target$820.36$915.00Buy$0.0000.00% ROIARQTArcutis Biotherapeutics10/29/2025Reiterated Rating$24.95$30.00Buy$0.0000.00% ROIALKSAlkermes10/22/2025Reiterated Rating$31.74Neutral$0.0000.00% ROIPRAXPraxis Precision Medicines10/16/2025Boost Price Target$162.71$232.00Buy$0.0000.00% ROICABACabaletta Bio10/10/2025Reiterated Rating$2.85$16.00Buy$0.0000.00% ROIPTGXProtagonist Therapeutics10/8/2025Reiterated Rating$65.47$80.00Buy$0.0000.00% ROIOTLKOncobiologics9/30/2025Reiterated Rating$1.06Neutral$0.0000.00% ROIROIVRoivant Sciences9/18/2025Boost Price Target$15.28$20.00Buy$0.0000.00% ROIPTGXProtagonist Therapeutics9/17/2025Reiterated Rating$60.57$80.00Buy$0.0000.00% ROIALKSAlkermes9/9/2025Reiterated Rating$28.45$46.00Neutral$0.0000.00% ROIRAPPRapport Therapeutics9/8/2025Boost Price Target$14.36$34.00Buy$0.0000.00% ROIIMVTImmunovant9/4/2025Reiterated Rating$16.70$35.00Buy$0.0000.00% ROIRZLTRezolute9/3/2025Reiterated Rating$7.17$14.00Buy$0.0000.00% ROIOTLKOncobiologics8/29/2025Reiterated Rating$1.09Neutral$0.0000.00% ROIEVOEvotec8/14/2025Lower Price Target$3.81$7.00Buy$0.0000.00% ROIBHVNBiohaven8/12/2025Reiterated Rating$13.42$30.00Buy$0.0000.00% ROIEOLSEvolus8/6/2025Lower Price Target$8.91$20.00Buy$0.0000.00% ROIRAPPRapport Therapeutics8/6/2025Initiated Coverage$14.43$31.00Buy$0.0000.00% ROIPRAXPraxis Precision Medicines8/5/2025Reiterated Rating$51.09$115.00Buy$0.0000.00% ROIARGXargenex8/1/2025Boost Price Target$670.33$774.00Buy$0.0000.00% ROIALKSAlkermes7/21/2025Reiterated Rating$26.37$46.00Neutral$0.0000.00% ROIPRAXPraxis Precision Medicines7/18/2025Reiterated Rating$54.94$105.00Buy$0.0000.00% ROIIRONDisc Medicine7/3/2025Reiterated Rating$53.17$118.00Buy$0.0000.00% ROIARGXargenex7/1/2025Reiterated Rating$551.22$720.00Buy$000.0000.00% ROICRNXCrinetics Pharmaceuticals6/27/2025Reiterated Rating$29.99$81.00Buy$00.0000.00% ROIROIVRoivant Sciences6/18/2025Reiterated Rating$11.11$18.00Buy$00.0000.00% ROIIRONDisc Medicine6/17/2025Reiterated Rating$52.02$118.00Buy$00.0000.00% ROISAGESage Therapeutics6/17/2025Reiterated Rating$9.07$12.00Neutral$0.0000.00% ROICABACabaletta Bio6/11/2025Reiterated Rating$1.75$25.00Buy$0.0000.00% ROIARGXargenex6/10/2025Reiterated Rating$583.62$720.00Buy$000.0000.00% ROIPTGXProtagonist Therapeutics6/3/2025Reiterated Rating$50.15$80.00Buy$00.0000.00% ROIROIVRoivant Sciences5/28/2025Reiterated Rating$10.76$18.00Buy$00.0000.00% ROIPTGXProtagonist Therapeutics5/19/2025Reiterated Rating$44.49$80.00Buy$000.0000.00% ROIXENEXenon Pharmaceuticals5/13/2025Reiterated Rating$35.85$53.00Buy$00.0000.00% ROIPRAXPraxis Precision Medicines5/1/2025Reiterated Rating$37.64$105.00Buy$000.0000.00% ROICHRSCoherus Oncology4/29/2025Reiterated Rating$1.03$7.00Buy$0.0000.00% ROIRZLTRezolute4/28/2025Reiterated Rating$3.68$14.00Buy$0.0000.00% ROIVRDNViridian Therapeutics4/23/2025Reiterated Rating$13.76$34.00Buy$00.0000.00% ROIROIVRoivant Sciences4/21/2025Reiterated Rating$10.22$18.00Buy$00.0000.00% ROIEOLSEvolus4/10/2025Reiterated Rating$10.37$27.00Buy$0.0000.00% ROIPTGXProtagonist Therapeutics4/10/2025Reiterated Rating$40.42$80.00Buy$000.0000.00% ROIARGXargenex4/8/2025Reiterated Rating$548.93$720.00Buy$000.0000.00% ROIDAREDare Bioscience4/1/2025Reiterated Rating$2.89$12.00Buy$0.0000.00% ROICABACabaletta Bio4/1/2025Reiterated Rating$1.39$25.00Buy$0.0000.00% ROISCPHscPharmaceuticals3/20/2025Reiterated Rating$3.04$18.00Buy$0.0000.00% ROIIMVTImmunovant3/19/2025Reiterated Rating$18.71$51.00Buy$00.0000.00% ROITrump's gold order: the announcement they won't put on the front page (Ad)On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.Request the free guide in 30 seconds and get positioned nowCHRSCoherus Oncology3/11/2025Reiterated Rating$1.04$7.00Buy$0.0000.00% ROIPTGXProtagonist Therapeutics3/10/2025Reiterated Rating$38.35$54.00Buy$00.0000.00% ROIEOLSEvolus3/5/2025Reiterated Rating$14.35$27.00Buy$0.0000.00% ROIBHVNBiohaven3/4/2025Reiterated Rating$30.50$54.00Buy$00.0000.00% ROISCPHscPharmaceuticals3/3/2025Reiterated Rating$3.28$18.00Buy$0.0000.00% ROIPRAXPraxis Precision Medicines3/3/2025Lower Price Target$38.60$105.00Buy$000.0000.00% ROIAPLSApellis Pharmaceuticals3/3/2025Reiterated Rating$25.15$57.00Buy$00.0000.00% ROIPTGXProtagonist Therapeutics3/3/2025Reiterated Rating$39.03$54.00Buy$00.0000.00% ROIARGXargenex2/28/2025Boost Price Target$624.70$720.00Buy$000.0000.00% ROINERVMinerva Neurosciences2/26/2025Reiterated Rating$1.79$5.00Neutral$0.0000.00% ROITBPHTheravance Biopharma2/25/2025Reiterated Rating$8.86$15.00Buy$00.0000.00% ROIPTGXProtagonist Therapeutics2/24/2025Boost Price Target$38.75$54.00Buy$00.0000.00% ROIOTLKOncobiologics2/18/2025Lower Price Target$1.87$3.00Buy$0.0000.00% ROICABACabaletta Bio2/18/2025Reiterated Rating$2.34$25.00Buy$0.0000.00% ROIEOLSEvolus2/14/2025Reiterated Rating$15.04$27.00Buy$0.0000.00% ROIALKSAlkermes2/13/2025Reiterated Rating$33.50$46.00Neutral$00.0000.00% ROIAPLSApellis Pharmaceuticals2/13/2025Reiterated Rating$28.51$57.00Buy$00.0000.00% ROIRZLTRezolute2/13/2025Reiterated Rating$4.79$14.00Buy$0.0000.00% ROISAGESage Therapeutics2/12/2025Reiterated Rating$7.19$12.00Neutral$0.0000.00% ROIROIVRoivant Sciences2/11/2025Reiterated Rating$10.55$18.00Buy$00.0000.00% ROIPTGXProtagonist Therapeutics2/7/2025Reiterated Rating$37.75$50.00Buy$00.0000.00% ROIIMVTImmunovant2/7/2025Reiterated Rating$20.39$51.00Buy$00.0000.00% ROIRZLTRezolute2/5/2025Reiterated Rating$5.50$14.00Buy$0.0000.00% ROICHRSCoherus Oncology1/23/2025Reiterated Rating$1.31$7.00Buy$0.0000.00% ROIEOLSEvolus1/22/2025Reiterated Rating$13.48$27.00Buy$0.0000.00% ROIIRONDisc Medicine1/21/2025Reiterated Rating$61.41$118.00Buy$00.0000.00% ROICABACabaletta Bio1/17/2025Reiterated Rating$2.43$25.00Buy$0.0000.00% ROIOTLKOncobiologics1/17/2025Reiterated Rating$2.19$30.00Buy$0.0000.00% ROIAPLSApellis Pharmaceuticals1/14/2025Reiterated Rating$28.59$57.00Buy$00.0000.00% ROIARGXargenex1/14/2025Reiterated Rating$671.62$717.00Buy$000.0000.00% ROICRNXCrinetics Pharmaceuticals1/13/2025Reiterated Rating$40.59$81.00Buy$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageThe Goldman Sachs GroupUBS GroupCitigroupBarclaysMorgan StanleyRoyal Bank Of CanadaWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank AktiengesellschaftStifel NicolausRaymond James Financial Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.